Meeder Advisory Services, Inc.
Position in ALNY — Alnylam Pharmaceuticals, Inc.
CIK 1792167
DUBLIN, OH
Position in ALNY
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$484,959
-$128,143 QoQ
Shares Held
1,611
-13.1% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#487
of 784 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ALNY Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Meeder Advisory Services, Inc. holds $10,646,226 across 17 Biotechnology names. ALNY ranks #7 (4.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
6,415 | $3,186,522 | |
| 2 | RPRX |
Royalty Pharma plc
|
19,242 | $1,078,898 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,311 | $817,460 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
3,922 | $734,512 | |
| 5 | IONS |
Ionis Pharmaceuticals Inc
|
7,660 | $607,361 | |
| 6 | MRNA |
Moderna, Inc.
|
7,734 | $541,612 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
This page
|
1,611 | $484,959 | |
| 8 | PCVX |
Vaxcyte, Inc.
|
7,785 | $452,542 |
All Filings in ALNY
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $484,959 | 1,611 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $613,102 | 1,853 | Shares | Sole | 2026-05-07 | |
| 2025-12-31 | $730,880 | 1,838 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $861,384 | 1,889 | Shares | Sole | 2025-10-24 | |
| 2025-06-30 | $366,851 | 1,125 | Shares | Sole | 2025-08-07 | |
| 2025-03-31 | $264,079 | 978 | Shares | Sole | 2025-05-07 | |
| 2024-12-31 | $213,190 | 906 | Shares | Sole | 2025-02-12 | |
| 2024-09-30 | $256,602 | 933 | Shares | Sole | 2024-11-07 | |
| No filing history on record for this holder in this stock. | ||||||